Chris Granger, MD FACC

Dr. Christopher Granger is a Professor of Medicine in the Division of Cardiology at Duke University. He is Director of the Cardiac Care Unit and co-director of cardiovascular clinical trials at the Duke Clinical Research Institute. He is a Fellow of the American College of Cardiology and of the European Society of Cardiology. He is Associate Editor of the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the European Heart Journal. He is on the Board of External Experts of the National Heart, Lung and Blood Institute (NHLBI) and on the clinical trials review committee for CIHR. He is on various committees for the American Heart Association and American College of Cardiology.

His primary research interest is in conduct and methodology of large randomized clinical trials in heart disease. He has co-authored over 250 peer-reviewed manuscripts. He has recently coordinated the Duke Clinical Research Institutes’ activities in the ASSENT-4 PCI, OASIS-5 and -6, and APEX-AMI trials that evaluated acute MI reperfusion and antithrombotic strategies; and the CHARM trial that evaluated angiotensin receptor blockers for heart failure. He is co-chairman of the Steering Committee of the ARISTOTLE trial assessing an oral factor Xa inhibitor for stroke prevention in atrial fibrillation. He is co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) project that is a North Carolina state-wide program to improve reperfusion care for acute myocardial infarction.

Reorganizing Acute MI Care: What Next in Canada and the United States

Download presentation (PDF)

Clinical Trials: Why They Fail to Meet Expectations

Download presentation (PDF)